Viridian Therapeutics, Inc./DE (VRDN) Total liabilities 2016–2025
Viridian Therapeutics, Inc./DE (VRDN) total liabilities at each fiscal year-end, per SEC filings.
$177.3MFY2025 · since FY2016: $9.7M → $177.3M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $177.3M | +150.5% |
| FY2024 | $70.8M | +46.2% |
| FY2023 | $48.4M | +20.9% |
| FY2022 | $40.0M | +150.3% |
| FY2021 | $16.0M | +42.6% |
| FY2020 | $11.2M | -22.7% |
| FY2019 | $14.5M | -2.0% |
| FY2018 | $14.8M | +6.0% |
| FY2017 | $14.0M | +44.0% |
| FY2016 | $9.7M | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice
More VRDN financial trends
VRDN RevenueVRDN Net incomeVRDN Net marginVRDN Gross profitVRDN Gross marginVRDN Operating incomeVRDN Operating marginVRDN Operating cash flowVRDN Free cash flowVRDN Capital expendituresVRDN Return on equityVRDN Stock buybacksVRDN Dividends paidVRDN Total assetsVRDN Shareholders’ equityVRDN overview →